Canada: First Class Action Win For The Pharmaceutical Industry In Quebec

Goyette v. GlaxoSmithKline Inc.

On August 17, 2009, Justice Mark G. Peacock of the Quebec Superior Court ruled in favour of the respondent GlaxoSmithKline Inc. (GSK), represented by Ogilvy Renault, dismissing a Motion for Authorization to Institute a Class Action (the "Motion for Authorization") made by the petitioner on behalf of all persons residing in Canada who have experienced dependency and withdrawal problems owing to the use of the antidepressant medication marketed under the name PAXIL. The petitioner contended that GSK had introduced PAXIL to the market without ensuring its safety, failed to inform health professionals, physicians and consumers of the risks associated with discontinuing this medication or reducing the dose, and misrepresented the facts in regard thereto. Accordingly, she claimed compensation on behalf of the members for physical, economic and moral damages suffered, along with punitive damages. The Court refused to allow a class action to be brought, on the basis that the three tests set out in paragraphs (a), (b) and (d) of article 1003 of the Code of Civil Procedure had not been met.


It should be noted that the Motion for Authorization had been made before the Code of Civil Procedure was amended in 2003, when appropriate evidence could still be filed without leave of the Court. In support of its contestation, GSK was able to present evidence to the Court with respect to the application of the tests in article 1003 C.C.P., in the form of cross-examinations of the petitioner on her affidavit, along with the affidavit of an expert to the effect that an individual examination of each member would be required before it could be concluded that the alleged symptoms were related to discontinuing PAXIL or reducing the dose.

Among other things, the examinations revealed that the petitioner had agreed to take PAXIL after consulting her doctor, with whom she had read the entry in the CPS (Compendium of Pharmaceutical Specialties/Compendium des produits et spécialités pharmaceutiques) and who had confirmed to her that there would be no risk associated with stopping treatment. Listed in the CPS under possible adverse effects were a range of symptoms, described as mild and transient, and under adverse experiences reported, withdrawal syndrome and drug dependence, described as rare. The petitioner stated that she had experienced severe symptoms after stopping treatment and, basing herself on certain U.S. and British news reports and articles, a U.S. website and a list of individuals who had signed up on her attorneys' website, maintained that other individuals had experienced similar symptoms.

I. Article 1003 (a) C.C.P. – Identical, similar or related questions

The Court begins by recalling the obligation that Quebec law imposes on a pharmaceutical manufacturer to inform consumers of the risks associated with a medication that it sells. It acknowledges that the manufacturer meets that obligation by disclosing the risks to a competent intermediary, according to the recognized legal principle known as the "learned intermediary rule." The Court notes that one means by which a pharmaceutical manufacturer can provide adequate information about the risks associated with a medication to the physicians who will be prescribing it is to disclose them in the CPS, on which the petitioner's Motion for Authorization is based.

In connection with the analysis of the test set out in article 1003 (a), the Court lays down a first important principle.

Contrary to previous rulings in pharmaceutical cases, the Court establishes that in Quebec, the question of whether punitive damages should be awarded under the Consumer Protection Act for failure to inform cannot constitute a common question since it requires an individual analysis. Indeed, only when the members of the prospective group have proven physical, psychological, economic and moral damages on the basis of individual hearings and the amounts of those damages have been decided individually can the Court consider what, if any, amount should be awarded as punitive damages, based on the criteria set out in article 1621 C.C.Q., which requires the Court to assess punitive damages in light of all the appropriate circumstances, including in particular the extent of the reparation for which the debtor is already liable to the creditor.

The Court adopts a second important principle, acknowledged by the Quebec Court of Appeal in Voisins du train de banlieue de Blainvile Inc c. Agence métropolitaine de transport,1 which requires there to be a possibility of establishing collective prejudice in order for the test in article 1003 (a) C.C.P. to be met. In the case at issue here, the Court finds that establishing collective prejudice is not possible since the alleged symptoms, such as headaches, dizziness, vertigo or insomnia, are susceptible of infinite variation as to their subjective nature, duration and intensity.

Lastly, the Court acknowledges the importance of causality, finding that civil liability on the part of GSK could not be established without multiple factors being examined, including the nature of the symptoms suffered by the members and whether or not they were described in the CPS; the information received from the treating physician or the pharmacist, and the causal connection between the symptoms and the use of PAXIL. The Court goes on to accept the expert opinion to the effect that an individual medical examination of each member would be required in order to establish such a causal connection between the existence of the alleged symptoms and discontinuation of treatment with PAXIL, noting that the mere fact that symptoms are alleged to have been suffered immediately after treatment was stopped or reduced cannot serve, in itself, to establish such a causal connection without considering other factors which could have caused those symptoms.

This case thus marks the first time in Quebec where, in a matter involving a pharmaceutical product, the fact that an individual examination of each member would be needed in order to establish liability on the part of the respondent manufacturer has prevented a class action from being authorized on the basis that the test of article 1003 (a) C.C.P. has not been met. Unlike certain prior decisions which appear to have skirted around the necessity of establishing a causal connection between the fault and the prejudice alleged, the Court has declined to allow a class action to proceed against a pharmaceutical company where the only common question to be decided would involve determining whether fault had occurred. In the Court's view, judicial economy would not be served by allowing an action to go ahead which would in reality require an individual trial on the merits for each member in order to establish civil liability on the part of the manufacturer (based on fault, prejudice and a causal connection).

II. Article 1003 (b) C.C.P. – Facts do not seem to justify conclusions sought

In the Court's view, the petitioner does not have a case against the manufacturer based on failure to provide sufficient information on the risks associated with stopping treatment with PAXIL since the alleged symptoms were disclosed in the CPS. The judge also bases his conclusion on the petitioner's admission that her treating physician confirmed to her that the symptoms she reportedly suffered were not linked to discontinuation of PAXIL. Lastly, the Court notes that, unlike other cases that have involved pharmaceutical products, the petitioner did not file an expert report establishing that the symptoms were connected with discontinuation of treatment.

As for the appearance of right in regard to the other members of the group, the Court notes the failure to allege sufficient facts purporting to support that other members of the group suffered symptoms related to discontinuation of PAXIL. Indeed, the petitioner based her proceedings solely on a list of individuals who she says signed up on her attorneys' website, and on Internet articles and documents originating from U.S. or British sources. The Court finds that her attorneys' website does not in itself constitute evidence, without an explanation of the context, and that even taking the foreign references as proven, they would not suffice to establish GSK's civil liability toward members in Canada for failure to disclose, in the CPS in Canada, risks associated with discontinuation of treatment with PAXIL.

III. Article 1003 (d) C.C.P. – Petitioner not an adequate representative

In light of the evidence presented, the Court finds that the petitioner is not in a position to represent the members adequately for the following three reasons: 1) she does not have an individual case to make against GSK; 2) she showed a singular lack of interest in the class action that she was seeking to have authorized in that she never spoke to any member of the group, does not know any member of the group and never tried to contact any of the individuals who she says signed up on her attorneys' website; and 3) she was unable to explain why the proceedings remained dormant for five years.

IV. National class

Even though, given its conclusions described above, the Court was not obliged to rule on the question of a national class, it nevertheless goes on to find that the criteria set out in article 3148 of the Civil Code of Québec necessary to justify a national class are not met. Indeed, the petitioner admitted not knowing whether GSK had any business activities in Quebec and she had not alleged that the PAXIL sold in Canada was in fact manufactured or distributed in Quebec or that the monograph for it was printed in Quebec. The Court refers to the recent Quebec Court of Appeal decision in Interinvest (Bermuda) Ltd c. Herzog,2 where it is established that the business activities implicated in the dispute must be connected to a place of business of the respondent in Quebec in order for the Quebec courts to be able to take jurisdiction in regard to every Canadian resident. Accordingly, the petitioner could only apply to represent members residing in Quebec since they alone could demonstrate that they had suffered damage in Quebec, according to one of the criteria set out in article 3148 C.C.Q.


This is the first Quebec case in which the Court has refused to authorize a class action involving a pharmaceutical product. It acknowledges that the class action is a procedural vehicle that should only be authorized where all the elements giving rise to civil liability can be established on a collective basis, namely, fault, prejudice and a causal connection between the two. In addition, it underscores the fact that while hearsay evidence may be admissible in connection with the test set out in article 1003 (b) C.C.P., the petitioner will nevertheless have to demonstrate a serious appearance of right. Lastly, contrary to certain decisions that appeared to suggest that the test in article 1003 (d) C.C.P. could be easily met, this decision advocates a more restrictive and rigorous approach to that test.


1 2007 QCCA 236

2 2009 QCCA 1428

About Ogilvy Renault

Ogilvy Renault LLP is a full-service law firm with close to 450 lawyers and patent and trade-mark agents practicing in the areas of business, litigation, intellectual property, and employment and labour. Ogilvy Renault has offices in Montréal, Ottawa, Québec, Toronto, and London (England), and serves some of the largest and most successful corporations in Canada and in more than 120 countries worldwide. Find out more at

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.